Table 4. Integrative identification of critical HMTs in kidney cancer.
| Gene | CNA/Mutations | CNA/mRNA correlation | Expression | mRNA/survial | CNA/survival | Score |
|---|---|---|---|---|---|---|
| ASH1L | + | + | + | 3 | ||
| PRDM8 | + | 1 | ||||
| SETD1A | + | + | 2 | |||
| PRDM9 | + | 1 | ||||
| PRDM6 | + | + | + | 3 | ||
| EHMT1 | + | 1 | ||||
| NSD1 | + | + | + | + | + | 5 |
| WHSC1L1 | + | + | + | 3 | ||
| PRDM7 | + | 1 | ||||
| SUV420H1 | + | + | 2 | |||
| DOT1L | + | 1 | ||||
| SETD2 | ++ | + | + | 4 | ||
| EZH2 | + | + | + | 3 | ||
| MECOM | + | + | 2 | |||
| SETD5 | + | + | 2 | |||
| SETMAR | + | + | 2 | |||
| KMT2C | ++ | 2 | ||||
| KMT2E | + | 1 |
Notes:
CNA/Mutation, amplifcation, deletion or mutation; CNA/mRNA correlation, associations between CNA and gene expression; Expression, altered expression in RCC; mRNA/Survival, mRNA associated with patient survival; CNA/Survival, CNA associated with patient survival.